Title	New assessment
Number of Patients Screened	11
Number of Patients Enrolled	11
Number of Patients Evaluable for Toxicity	10
Number of Patients Evaluated for Efficacy	10
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 0 (0%)
Response Assessment SD	n = 6 (60%)
Response Assessment PD	n = 4 (40%)
Outcome Notes	Best overall response was stable disease in six patients (60%), and the 6‐month progression‐free survival rate was 50%.